Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Metabolic fitness of NAC1-deficient Tregs in the tumor microenvironment fuels tumor growth
Anil Kumar, Jugal Kishore Das, Hao-Yun Peng, Liqing Wang, Darby Jane Ballard, Yijie Ren, Xiaofang Xiong, Xingcong Ren, Jin-Ming Yang, Paul de Figueiredo, Jianxun Song
Anil Kumar, Jugal Kishore Das, Hao-Yun Peng, Liqing Wang, Darby Jane Ballard, Yijie Ren, Xiaofang Xiong, Xingcong Ren, Jin-Ming Yang, Paul de Figueiredo, Jianxun Song
View: Text | PDF
Research Article Immunology

Metabolic fitness of NAC1-deficient Tregs in the tumor microenvironment fuels tumor growth

  • Text
  • PDF
Abstract

The nucleus accumbens-associated protein 1 (NAC1) has recently emerged as a pivotal factor in oncogenesis by promoting glycolysis. Deletion of NAC1 in regulatory T cells (Tregs) has been shown to enhance FoxP3 stability, a suppressor of glycolysis. This study delves into the intriguing dual role of NAC1, uncovering that Treg-specific deletion of NAC1 fosters metabolic fitness in Tregs, thereby promoting tumorigenesis. Our results unveil that NAC1-deficient Tregs exhibited prolonged survival and heightened function, particularly in acidic environments. Mechanistically, we find that NAC1-deficient Tregs adapted to adverse conditions by upregulating FoxP3 expression, engaging in CD36-mediated lipid metabolism, and enhancing peroxisome proliferator–activated receptor gamma coactivator 1-alpha–regulated mitochondrial function. In mouse tumor xenograft models, NAC1-deficient mice demonstrated increased susceptibility to tumor growth. Notably, Tregs lacking NAC1 not only displayed elevated lipid metabolism and mitochondrial fitness but also exhibited enhanced tumoral infiltration. Adoptive Treg transfer experiments further underscored the supportive role of NAC1-deficient Tregs in tumor growth. These findings suggest that modulating NAC1 expression in FoxP3+ Tregs could serve as a promising approach to augment antitumor immunity. Understanding the intricate interplay between NAC1 and Tregs opens avenues for potential therapeutic strategies targeting the tumor microenvironment.

Authors

Anil Kumar, Jugal Kishore Das, Hao-Yun Peng, Liqing Wang, Darby Jane Ballard, Yijie Ren, Xiaofang Xiong, Xingcong Ren, Jin-Ming Yang, Paul de Figueiredo, Jianxun Song

×

Figure 3

NAC1-KO Tregs show enhanced functional activity of Tregs in acidic environments.

Options: View larger image (or click on image) Download as PowerPoint
NAC1-KO Tregs show enhanced functional activity of Tregs in acidic envir...
(A) CD8+ cells were labeled with CFSE and cocultured with WT or NAC1-KO Tregs (1:1) in the presence of anti-CD3 and -CD28 antibodies. Histogram of representative experiment showing the proliferation of CD8+ cells in the CM-treated culture. (B) Quantification analysis of the in vitro suppression assay (n = 3). (C) Representative histogram of the expression of GzmB in WT and NAC1-KO Tregs after 48-hour treatment with LA or CM (n = 5). (D) Quantification of differential expression of GzmB in WT versus NAC1-KO Tregs after the indicated treatment for 48 hours (n = 5). (E) Representative histogram of TGF-β expression in WT Tregs and NAC1-KO Tregs after 48-hour treatment with LA or CM (n = 5). (F) Quantification of differential expression of TGF-β in WT Tregs versus NAC1-KO Tregs after the indicated treatment for 48 hours (n = 5). The data are represented as mean ± SEM. *: P ≤ 0.05, **: P ≤ 0.01, ***: P ≤ 0.001, 2-way ANOVA with multiple comparisons correction using GraphPad Prism.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts